NCT05911009 - To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

June 26, 2024

Study Completion Date

September 4, 2024

Conditions

Long Covid

Interventions

DRUG

BC 007 or matching placebo

Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design

Trial Locations (16)

1100

Klinik Favoriten - Wiener Gesundheitsverbund, Vienna

1210

Klinik Floridsdorf - Wiener Gesundheitsverbund, Vienna

8037

Stadtspital Zurich Waid, Zurich

10117

Charité - Universitätsmedizin Berlin, Berlin

14089

Krankenhaus Havelhöhe, Berlin

28223

Hospitalario Universitario Quironsalud Madrid, Madrid

29010

Hospital General de Málaga, Málaga

41013

University Hospital Virgen Del Rocio S.L., Seville

48149

Universitätsklinikum Münster, Münster

50937

Universitätsklinikum Köln, Cologne

69120

Universitätsklinikum Heidelberg, Heidelberg

79106

Universitätsklinikum Freiburg, Freiburg im Breisgau

91054

Universitätsklinikum Erlangen, Erlangen

00380

Terveystalo Helsinki Sleep Clinic, Helsinki

07747

Universitätsklinikum Jena, Jena

03010

Hospital General Universitario de Alicante, Alicante